Cargando…

Newcastle Disease Virus as a Vaccine Vector for SARS-CoV-2

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in more than 16 million infections and more than 600,000 deaths worldwide. There is an urgent need to develop a safe and effective vaccine against SARS-CoV-2. Currently, several strategies are being pursued to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shirvani, Edris, Samal, Siba K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459537/ https://www.ncbi.nlm.nih.gov/pubmed/32751194 http://dx.doi.org/10.3390/pathogens9080619

Ejemplares similares

Comparative Protective Efficacies of Novel Avian Paramyxovirus-Vectored Vaccines against Virulent Infectious Bronchitis Virus in Chickens
por: Shirvani, Edris, et al.
Publicado: (2020)

Innovation in Newcastle Disease Virus Vectored Avian Influenza Vaccines
por: Kim, Shin-Hee, et al.
Publicado: (2019)

Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines
por: Kim, Shin-Hee, et al.
Publicado: (2016)

A Recombinant Newcastle Disease Virus (NDV) Expressing S Protein of Infectious Bronchitis Virus (IBV) Protects Chickens against IBV and NDV
por: Shirvani, Edris, et al.
Publicado: (2018)

Author Correction: A Recombinant Newcastle Disease Virus (NDV) Expressing S Protein of Infectious Bronchitis Virus (IBV) Protects Chickens against IBV and NDV
por: Shirvani, Edris, et al.
Publicado: (2020)

Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus
por: Manoharan, Vinoth K., et al.
Publicado: (2018)

Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease
por: Warner, Bryce M., et al.
Publicado: (2021)

Contributions of HA1 and HA2 Subunits of Highly Pathogenic Avian Influenza Virus in Induction of Neutralizing Antibodies and Protection in Chickens
por: Shirvani, Edris, et al.
Publicado: (2020)

Development of a recombinant Newcastle disease virus-vectored vaccine for infectious bronchitis virus variant strains circulating in Egypt
por: Abozeid, Hassanein H., et al.
Publicado: (2019)

Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans
por: DiNapoli, Joshua M., et al.
Publicado: (2009)

Co-expression of the Hemagglutinin and Neuraminidase by Heterologous Newcastle Disease Virus Vectors Protected Chickens against H5 Clade 2.3.4.4 HPAI Viruses
por: Cho, Yeonwoo, et al.
Publicado: (2018)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

Effect of fusion protein cleavage site sequence on generation of a genotype VII Newcastle disease virus vaccine
por: Manoharan, Vinoth K., et al.
Publicado: (2018)

Evaluation of fusion protein cleavage site sequences of Newcastle disease virus in genotype matched vaccines
por: Kim, Shin-Hee, et al.
Publicado: (2017)

Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response
por: DiNapoli, Joshua M., et al.
Publicado: (2010)

A recombinant avian paramyxovirus serotype 3 expressing the hemagglutinin protein protects chickens against H5N1 highly pathogenic avian influenza virus challenge
por: Shirvani, Edris, et al.
Publicado: (2020)

Intranasal vaccination of hamsters with a Newcastle disease virus vector expressing the S1 subunit protects animals against SARS-CoV-2 disease
por: Díaz, Manolo Fernández, et al.
Publicado: (2022)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Newcastle Disease Virus Fusion Protein Is the Major Contributor to Protective Immunity of Genotype-Matched Vaccine
por: Kim, Shin-Hee, et al.
Publicado: (2013)

Author Correction: A recombinant avian paramyxovirus serotype 3 expressing the hemagglutinin protein protects chickens against H5N1 highly pathogenic avian influenza virus challenge
por: Shirvani, Edris, et al.
Publicado: (2020)

Role of fusion protein cleavage site in the virulence of Newcastle disease virus
por: Panda, Aruna, et al.
Publicado: (2004)

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate
por: Sun, Weina, et al.
Publicado: (2020)

Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs
por: Lara-Puente, Jesús Horacio, et al.
Publicado: (2021)

Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens
por: Kim, Shin-Hee, et al.
Publicado: (2014)

Effects of Naturally Occurring Six- and Twelve-Nucleotide Inserts on Newcastle Disease Virus Replication and Pathogenesis
por: Paldurai, Anandan, et al.
Publicado: (2014)

Sequence analysis of fusion protein gene of Newcastle disease virus isolated from outbreaks in Egypt during 2006
por: Mohamed, Mahmoud HA, et al.
Publicado: (2011)

Complete Genome Sequence of a Highly Virulent Newcastle Disease Virus Currently Circulating in Mexico
por: Xiao, Sa, et al.
Publicado: (2013)

Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines
por: Choi, Kang-Seuk
Publicado: (2017)

Mucosal delivery of RNA vaccines by Newcastle disease virus vectors
por: García-Sastre, Adolfo
Publicado: (2022)

The human ACE-2 receptor binding domain of SARS-CoV-2 express on the viral surface of the Newcastle disease virus as a non-replicating viral vector vaccine candidate
por: Jung, Bo-Kyoung, et al.
Publicado: (2022)

Newcastle Disease Virus Vectored Bivalent Vaccine against Virulent Infectious Bursal Disease and Newcastle Disease of Chickens
por: Dey, Sohini, et al.
Publicado: (2017)

Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges
por: Khattar, Sunil K., et al.
Publicado: (2015)

Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer Therapy
por: Vigil, Adam, et al.
Publicado: (2008)

A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine
por: Sun, Weina, et al.
Publicado: (2020)

Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines
por: Rijkers, Ger T., et al.
Publicado: (2021)

Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys
por: Le Nouën, Cyril, et al.
Publicado: (2022)

Generation by Reverse Genetics of an Effective, Stable, Live-Attenuated Newcastle Disease Virus Vaccine Based on a Currently Circulating, Highly Virulent Indonesian Strain
por: Xiao, Sa, et al.
Publicado: (2012)

Intramuscular administration of recombinant Newcastle disease virus expressing SARS-CoV-2 spike protein protects hACE-2 TG mice against SARS-CoV-2 infection
por: Kim, Deok-Hwan, et al.
Publicado: (2023)

Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1
por: Khattar, Sunil K., et al.
Publicado: (2010)

Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
por: Mendonça, Samir Andrade, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7f4htv7d38bfiudv5mqem890co